Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.

Muntoni F, Tejura B, Spinty S, Roper H, Hughes I, Layton G, Davies KE, Harriman S, Tinsley J.

Clin Pharmacol Drug Dev. 2019 Jan 16. doi: 10.1002/cpdd.642. [Epub ahead of print]

PMID:
30650257
2.

A new forum for research on research integrity and peer review.

Harriman SL, Kowalczuk MK, Simera I, Wager E.

Res Integr Peer Rev. 2016 May 3;1:5. doi: 10.1186/s41073-016-0010-y. eCollection 2016.

3.

When are clinical trials registered? An analysis of prospective versus retrospective registration.

Harriman SL, Patel J.

Trials. 2016 Apr 15;17:187. doi: 10.1186/s13063-016-1310-8.

4.

Retrospective analysis of the quality of reports by author-suggested and non-author-suggested reviewers in journals operating on open or single-blind peer review models.

Kowalczuk MK, Dudbridge F, Nanda S, Harriman SL, Patel J, Moylan EC.

BMJ Open. 2015 Sep 29;5(9):e008707. doi: 10.1136/bmjopen-2015-008707.

5.

The C-reactive protein: prealbumin ratio as a predictor of successful surgical closure of gastrointestinal fistulas.

Harriman S, Rodych N, Hayes P, Moser MA.

Am Surg. 2015 Feb;81(2):E73-4. No abstract available.

PMID:
25642862
6.

Text recycling: acceptable or misconduct?

Harriman S, Patel J.

BMC Med. 2014 Aug 16;12:148. doi: 10.1186/s12916-014-0148-8.

7.

The ethics and editorial challenges of internet-based research.

Harriman S, Patel J.

BMC Med. 2014 Jul 15;12:124. doi: 10.1186/s12916-014-0124-3.

8.

Identification of saturated and unsaturated fatty acids released during microsomal incubations.

Bushee JL, Liang G, Dunne CE, Harriman SP, Argikar UA.

Xenobiotica. 2014 Aug;44(8):687-95. doi: 10.3109/00498254.2014.884253. Epub 2014 Feb 6.

PMID:
24502389
9.

Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).

Kamel A, Harriman S.

Drug Discov Today Technol. 2013 Spring;10(1):e177-89. doi: 10.1016/j.ddtec.2012.09.011. Review.

PMID:
24050247
10.

Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance.

Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini G, Liric Rajlic I, Obach RS.

J Clin Pharmacol. 2013 Feb;53(2):178-91. doi: 10.1177/0091270012440282. Epub 2013 Jan 24.

PMID:
23436263
11.

Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state.

Lombardo F, Waters NJ, Argikar UA, Dennehy MK, Zhan J, Gunduz M, Harriman SP, Berellini G, Rajlic IL, Obach RS.

J Clin Pharmacol. 2013 Feb;53(2):167-77. doi: 10.1177/0091270012440281. Epub 2013 Jan 24. Erratum in: J Clin Pharmacol. 2013 May;53(5):574.

PMID:
23436262
12.

Oxidative ipso substitution of 2,4-difluoro-benzylphthalazines: identification of a rare stable quinone methide and subsequent GSH conjugate.

Gunduz M, Argikar UA, Kamel A, Colizza K, Bushee JL, Cirello A, Lombardo F, Harriman S.

Drug Metab Dispos. 2012 Nov;40(11):2074-80. doi: 10.1124/dmd.112.046268. Epub 2012 Jul 30.

PMID:
22851614
13.

In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase.

Kamel A, Colizza K, Gunduz M, Harriman S, Obach RS.

Xenobiotica. 2012 Apr;42(4):355-62. doi: 10.3109/00498254.2011.630490. Epub 2011 Nov 22.

PMID:
22106962
14.

The C-reactive protein-to-prealbumin ratio predicts fistula closure.

Harriman S, Rodych N, Hayes P, Moser MA.

Am J Surg. 2011 Aug;202(2):175-8. doi: 10.1016/j.amjsurg.2010.06.021. Epub 2011 May 23.

PMID:
21601827
15.

Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species.

Argikar UA, Mangold JB, Harriman SP.

Curr Top Med Chem. 2011;11(4):419-49. Review.

PMID:
21320068
16.

High-throughput analysis of in vitro cytochrome p450 inhibition samples using mass spectrometry coupled with an integrated liquid chromatography/autosampler system.

Brown A, Bickford S, Hatsis P, Amin J, Bell L, Harriman S.

Rapid Commun Mass Spectrom. 2010 Apr 30;24(8):1207-10. doi: 10.1002/rcm.4461. No abstract available.

PMID:
20301107
17.

Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies.

Gunduz M, Argikar UA, Baeschlin D, Ferreira S, Hosagrahara V, Harriman S.

Drug Metab Dispos. 2010 Mar;38(3):361-7. doi: 10.1124/dmd.109.030650. Epub 2009 Dec 11.

PMID:
20008038
18.

Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.

Bauer D, Whittington DA, Coxon A, Bready J, Harriman SP, Patel VF, Polverino A, Harmange JC.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4844-8. doi: 10.1016/j.bmcl.2008.07.080. Epub 2008 Jul 24.

PMID:
18682324
19.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Harmange JC, Weiss MM, Germain J, Polverino AJ, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, DiPietro L, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Martin MW, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Wang L, White RD, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1649-67. doi: 10.1021/jm701097z. Epub 2008 Mar 7.

PMID:
18324761
20.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.

J Med Chem. 2008 Mar 27;51(6):1668-80. doi: 10.1021/jm701098w. Epub 2008 Mar 7.

PMID:
18324759

Supplemental Content

Support Center